Introduction
Platelets and leukocytes have closely interlinked functions. Platelets are increasingly recognized to contribute to inflammation, 1 immunity, 2,3 atherogenesis, 4 cancer metastasis 5 and the separation of blood and lymphatic vasculature. 6 Concomitantly, leukocytes play a critical role in thrombo-inflammatory diseases, including ischemic stroke, myocardial infarction and deep vein thrombosis. 7 Megakaryocyte (MK)/platelet-specific conditional knockout (KO) mouse models have become invaluable means of determining the molecular mechanisms regulating platelet production and pathophysiological functions in which they are involved. The current model of choice for generating MK/platelet-specific conditional KO mice is the Platelet factor 4-Cre recombinase (Pf4-Cre) transgenic mouse, developed by Skoda and co-workers. 8 The Pf4-Cre mouse has been used in over 160 studies to date to generate a variety of MK/platelet-specific conditional KO mice (Supplemental Table 1 ), providing numerous novel insights into platelet production and function.
However, the utility of the Pf4-Cre strain to delineate the role of platelets from leukocytes is limited. Recent studies demonstrate transgene expression outside the MK lineage, including hematopoietic stem cells, a sub-population of circulating leukocytes and macrophages. [9] [10] [11] [12] Recombination in these cells can result in phenotypes unrelated to deletion of proteins in platelets, a case in point being reduced plasma levels of FXIII-A in F13a1 fl/fl ;Pf4-Cre mice being due to factor (F)XIII-A ablation in Pf4-expressing macrophages. 13 A particularly confounding issue with Pf4-Cre transgene is that a considerable proportion of leukocytes undergo recombination upon inflammatory stimulation, 9, 12 complicating in vivo experiments. Importantly, findings on broader Pf4-Cre expression are in agreement with reports on endogenous Pf4 (also referred to as C-X-C motif chemokine 4; Cxcl4) expression pattern.
Although this chemokine was for many years thought to be expressed exclusively in MKs and platelets; 14, 15 there is now unequivocal evidence that endogenous Pf4 is also expressed in a variety of immune cells, including monocytes, [16] [17] [18] [19] [20] macrophages, 13, 16, [18] [19] [20] [21] [22] [23] [24] microglia, 25, 26 dendritic cells, 20, 24, [27] [28] [29] [30] granulocytes, 31 mast cells, 32 T cells 12, 17 and B cells, 20, 24 either constitutively or upon stimulation. Moreover, broader endogenous Pf4 expression is also supported by gene expression databases. [33] [34] [35] Unexpectedly, endogenous Pf4 expression has also been described outside the hematopoietic lineage in a population of intestinal epithelial cells. 36 Moreover, Pf4-Cre-mediated recombination was also observed in a subset of epithelial cells in the colon, resulting in the development of colon cancer in Adenomatous polyposis coli fl/fl ;Pf4-Cre mice. 9 Thus, caution must be taken when interpreting phenotypes arising from Pf4-Cre-generated conditional KO mouse models. Notably, there are currently no alternative Cre deleter strains available that are specific for the MK lineage.
To overcome these limitations of the Pf4-Cre deleter strain, we developed a Gp1ba-Cre transgenic mouse model, utilizing the MK/platelet-specific endogenous Gp1ba locus to drive Cre expression. Gp1ba encodes the glycoprotein (GP)Ibα subunit of the GPIb-IX-V complex, the receptor for von Willebrand factor (vWF). 37 Our results demonstrate that the Gp1ba-Cre deleter mouse enables highly efficient and specific ablation of floxed genes in the MK lineage. We provide a new tool for generating MK/platelet-specific KO mice that allows researchers to differentiate the functional roles of platelets and leukocytes in any pathophysiological condition.
Materials and methods

Mouse models
All mice used were on a C57BL/6 background. The Gp1ba-Cre transgenic mouse was generated as described below. Membrane-targeted tandem dimer tomato/membrane-targeted green fluorescent protein (mT/mG) double fluorescent Cre reporter mice were obtained from Jackson Laboratory. 38 Pf4-Cre +/KI , Csk fl/fl , CD148 fl/fl , and Shp1 fl/fl mice were generated as previously described. 8, [39] [40] [41] 
Generation of Gp1ba-Cre transgenic mouse
The targeting strategy enabled the generation of a constitutive knock-in (KI) of a T2A- All other materials and methods along with the statistical analysis are described in supplemental Materials and methods.
Results
Generation of the Gp1ba-Cre transgenic mouse strain
The Gp1ba gene was selected to drive Cre expression, because it is well established that GPIbα is highly and specifically expressed in MKs and platelets. 44 The T2A sequence was employed in the targeted insertion strategy, which allows multiple proteins to be expressed from a single multi-cistronic transcript. 45 To enable the expression of the recombinase under control of the endogenous Gp1ba locus, T2A was inserted in-frame with improved-Cre (iCre) between the last amino acid and the translation termination codon in Gp1ba (Figure 1 ). Upon translation of the chimeric Gp1ba-T2A-iCre mRNA, the T2A sequence will lead to 'ribosome skipping', resulting in the co-expression of GPIbα and Cre as discrete proteins in cells where GPIbα is endogenously expressed. As a result of the T2A technology, the GPIbα protein is expected to possess an additional 17 amino acids (EGRGSLLTCGDVEENPG) at its Cterminus and a proline on the N-terminus of iCre. Gp1ba-Cre mice are viable, fertile, displayed no overt developmental or behavioral defects and are born at expected Mendelian frequencies (Supplemental Table 2 ).
Normal platelet count and minor changes in receptor expression
The Gp1ba-Cre mice used in the present study were heterozygous for the knock-in (KI) allele (Gp1ba-Cre +/KI ). Platelet count and other hematological parameters were normal in these mice, except platelet volume, which was increased by 18% ( Figure 2A and Supplemental   Table 3 ). To test whether expression of the GPIb-IX-V complex was affected, we measured surface receptor expression levels of each subunit of the complex, namely GPIbα, GPIbβ, GPIX and GPV, as well as GPVI, CLEC-2 and the integrins αIIbβ3 and α2
by flow cytometry ( Figure 2B ). GPIbα expression was reduced by 33%, likely accounting for the increase in platelet volume ( Figure 2B ). GPIbβ and GPIX were concomitantly reduced by 18% and 19%, respectively, whereas GPV expression was normal. In contrast, surface expression of the integrin αIIbβ3 was increased by 18%, likely reflecting the increase in platelet volume. No significant differences were detected in surface expression of integrin α2, GPVI and CLEC-2 ( Figure 2B ).
To better understand the consequences of the Gp1ba-Cre targeted insertion strategy on GPIbα expression and other platelet parameters, we analyzed mice homozygous for the KI allele (Gp1ba-Cre KI/KI ). These mice had a 49% reduction in platelet count, 71% increase in platelet volume, and reduced surface expression of GPIbα (72%), GPIbβ (51%), GPIX (51%), GPV (50%) compared with WT mice (Supplemental Figure 1 ). The relationship between GPIbα levels and platelet volume and count is well established both in humans and mice, 46, 47 and suggests that the targeted insertion might interfere with mRNA stability, translation or GPIbα protein stability or trafficking.
Normal platelet function and hemostasis
To study whether the reduction in GPIb-IX complex levels translate to aberrant platelet function in the Gp1ba-Cre +/KI mice, platelet aggregation and ATP secretion were measured in response to a range of platelet agonists. No differences were found in aggregation or secretion in response to collagen (3 and 10 µg/ml), the synthetic GPVI-specific agonist collagen-related peptide (CRP, 3 and 10 µg/ml), thrombin (0.06 and 0.1 U/ml), the thromboxane A2 analog U46619 (3 and 10 µM) or ADP (10 and 30 µM) ( Figure 3A and
Supplemental Figure 2 ). Recombinant botrocetin-2 (rBot2; 1 µg/ml) and mouse vWF (10 µg/ml) were used in combination to specifically test GPIb-IX-V-mediated platelet agglutination. 48 Despite the reduced expression of GPIb-IX complex on the platelet surface, no differences were observed in the function of GPIbα in platelets from Gp1ba-Cre +/KI mice ( Figure 3B ).
The ability of Gp1ba-Cre platelets to adhere and spread on a fibrinogen-coated surface under static conditions was subsequently assessed. Non-stimulated and thrombin preactivated Gp1ba-Cre platelets spread to the same extent as WT platelets on fibrinogen (Supplemental Figure 3 ), demonstrating normal integrin αIIbβ3-mediated functional responses.
To investigate whether minor defects described above translated into hemostatic complications in Gp1ba-Cre +/KI mice, we assessed tail bleeding following excision of a 5 mm portion of the tail tip. No significant differences in blood loss were observed in Gp1ba-Cre +/KI mice compared with WT mice (Supplemental Figure 4 ). Collectively, these findings demonstrate that platelet function is normal in Gp1ba-Cre +/KI mice. Gp1ba-Cre +/KI mice were used to generate conditional KO mice and as controls in all subsequent experiments.
Highly specific recombination in the MK lineage
The expression pattern of Cre is expected to mirror that of endogenous GPIbα in the Gp1ba- We measured recombination in platelets from peripheral blood using flow cytometry, by counting EGFP + events in the CD41 + (integrin αIIb + ) population. We found that 98.7%
and 99.9% of platelets were EGFP + , thus undergoing recombination in Gp1ba-Cre-and Pf4-Cre-generated mice, respectively ( Figure 4A ). Interestingly, 64.1% and 2.4% of mT/mG +/fl ;Gp1ba-Cre +/KI and mT/mG +/fl ;Pf4-Cre +/KI were EGFP + tdTomato + , respectively, suggesting recombination takes place later in Gp1ba-Cre-generated mice (Supplemental Figure 5 ). We next determined EGFP + fractions of TER-119 + (erythroid marker) cells and found that 0.1% and 0.2% of red blood cells expressed EGFP in mT/mG +/fl ;Gp1ba-Cre +/KI and mT/mG +/fl ;Pf4-Cre +/KI mice, respectively ( Figure 4A ). Subsequently, we quantified EGFP expression in CD45 + (pan-leukocyte marker) blood cells and found 0.3% EGFP + tdTomatoand 2.3% EGFP + tdTomato + cells in mT/mG +/fl ;Gp1ba-Cre +/KI mice.
Whereas the former population likely represents bona fide recombined cells, we cannot exclude the possibility that the latter population includes EGFP + platelet-leukocyte aggregates. Notably, we found that 25.6% of CD45 + cells were EGFP + tdTomatoin mT/mG +/fl ;Pf4-Cre +/KI mice, suggesting recombination in a large population of circulating leukocytes.
We next quantified EGFP-expressing bone marrow (BM) cells. We observed 0.7% EGFP + tdTomato -, 54.6% EGFP + tdTomato + and 42.9% EGFP -tdTomato + BM cells within the CD41 high (CD41 hi ) population in mT/mG +/fl ;Gp1ba-Cre +/KI mice ( Figure 4B ). When we gated on mature GPIbα hi MKs, we found 1.9% EGFP + tdTomato -, 72% EGFP + tdTomato + and 23% EGFP -tdTomato + cells in the same mouse model ( Figure 4B ). In contrast, in representing a common MK/erythroid progenitor population ( Figure 4B ). In contrast, 24.4% of TER-119 + BM cells were EGFP + tdTomatoin the mT/mG +/fl ;Pf4-Cre +/KI mice, suggesting recombination in maturing erythroid lineage cells in these mice. The lack of EGFP + or tdTomato + erythrocytes in either mouse model is most likely due to protein degradation during the long lifespan of these cells ( Figure 4A ).
We then investigated EGFP expression in different subsets of spleen cells. We found less than 0.3% EGFP + tdTomatomyeloid cells (CD11b + Gr-1 -), granulocytes (CD11b + Gr-1 hi ), conventional dendritic cells (CD11c hi B220 -), B cells (B220 + CD11c -) and T cells (CD3ε + F4/80 -) in mT/mG +/fl ;Gp1ba-Cre +/KI mice ( Figure 4C ). In addition, we observed 4.7% EGFP + tdTomato + macrophages (F4/80 + CD11b + ) in these mice, which either represent bona fide recombined macrophages or cells which have phagocytosed EGFP + platelets.
Strikingly, we detected high proportions of EGFP + tdTomatomyeloid and lymphoid cell subsets in mT/mG +/fl ;Pf4-Cre +/KI spleens, including 23.2% myeloid cells (CD11b + Gr-1 -), 25 .2% granulocytes (CD11b + Gr-1 hi ), 23.3% conventional dendritic cells (CD11c hi B220 -), 13 .8% B cells (B220 + CD11c -) and 14.1% T cells (CD3ε + F4/80 -) ( Figure 4C ). Furthermore, we identified 48% EGFP + tdTomato + macrophages (F4/80 + CD11b + ) in these mice, suggesting recombination in immature macrophages.
Collectively, these findings demonstrate Cre-mediated recombination in a large proportion of platelets and MKs in both Gp1ba-Cre +/KI and Pf4-Cre +/KI mice. However, the earlier onset of Pf4-Cre also results in recombination in ~15-50% of erythroid, myeloid and lymphoid cells, not observed in Gp1ba-Cre mice.
Similar platelet phenotypes
After establishing the lineage-specificity of Cre expression in hematopoietic cells, we sought to compare protein ablation efficiency and phenotypes of conditional KO mice generated with either Gp1ba-Cre or Pf4-Cre mouse. To achieve this, we crossed both deleter strains to Csk-39 , CD148-, 40 or Shp1-floxed mice 41 , respectively for direct comparison. Csk, CD148
and Shp1 are widely expressed in hematopoietic cells and have been implicated in regulating immune cell development and function. [39] [40] [41] 49 Protein Figure 5A ). Csk fl/fl ;Pf4-Cre +/KI mice showed a 71% reduction in platelet count, a 35% increase in platelet volume, an 85% reduction in GPVI and a 42% increase in G6b-B levels ( Figure 5B-C) . Importantly, Csk fl/fl ;Gp1ba-Cre +/KI mice exhibited a similar, but less severe platelet phenotype, including a 32% reduction in platelet count, a 15% increase in platelet volume, a 62% decrease in GPVI and a 37% increase in G6b-B levels ( Figure 5B -C).
Differences between the two models likely reflect incomplete Csk ablation in Csk fl/fl ;Gp1ba-
Cre +/KI platelets and can be explained by the later onset of Gp1ba-Cre transgene expression ( Figure 4B ). Notably, we found that white blood cell and lymphocyte counts were significantly elevated in the Csk fl/fl ;Pf4-Cre +/KI mice, but unaltered in the Csk fl/fl ;Gp1ba-Cre +/KI mice ( Figure 5D ), suggesting Csk deletion in lymphocytes in Csk fl/fl ;Pf4-Cre +/KI mice.
Surface receptor levels of CD148 on CD148 fl/fl ;Gp1ba-Cre +/KI and CD148 fl/fl ;Pf4-Cre +/KI platelets displayed 95.1% and 93.6% reduction, respectively, as determined by flow cytometry ( Figure 6A ). Surface levels of GPVI were reduced by 58% and 57% in the two mouse models, respectively ( Figure 6B ). CD148 fl/fl ;Gp1ba-Cre +/KI platelets showed remarkably similar aggregation responses to CD148 fl/fl ;Pf4-Cre +/KI platelets, including the previously described GPVI-specific aggregation defect in response to CRP and normal aggregation in response to thrombin ( Figure 6C ). 42, 50 Highly similar aggregation responses were observed to a range of CRP concentrations ( Figure 6D ), demonstrating that CD148 fl/fl ;Gp1ba-Cre +/KI platelets phenocopy their Pf4-Cre-generated counterparts. Figure 7B-C) . The motheaten phenotype arises from a spontaneous mutation in Shp1, leading to loss of Shp1 expression. 51 It is characterized by hyper-inflammatory and autoimmune responses whereby different hematopoietic cell subsets contribute to different aspects of the phenotype. 52 In contrast, none of the Shp1 fl/fl ;Gp1ba-Cre +/KI mice showed signs of the motheaten-like phenotype (Figure 7B ), suggesting that it is unlikely to be driven by the lack of platelet Shp1. To better understand the etiology of the inflammatory phenotype, we analyzed leukocyte counts in peripheral blood and spleen of these mice. Shp1 fl/fl ;Pf4-Cre +/KI mice showed significantly elevated monocyte, atypical lymphocyte (ALY) and large immature cell (LIC) counts, suggesting aberrant development of multiple leukocyte subsets. This was not the case in Shp1 fl/fl ;Gp1ba-Cre +/KI mice, which had normal blood counts ( Figure 7D ). Shp1 fl/fl ;Pf4-Cre +/KI mice displayed significantly increased spleen/body weight ratio, total splenocyte, granulocyte (Gr-1 hi F4/80 -CD11c -B220 -) and conventional dendritic cell (cDC; CD11c hi B220 -) counts, and activated cDCs (CD86 + ) ( Figure 7E ). All of these parameters were normal in Shp1 fl/fl ;Gp1ba-Cre +/KI mice ( Figure   7E ), highlighting the lack of transgene expression in these other lineages. These results strongly suggest that Shp1 is ablated outside of the MK lineage in the Shp1 fl/fl ;Pf4-Cre +/KI mice, supporting findings from mT/mG fl/+ ;Pf4-Cre +/KI mice ( Figure 4A-C) .
No associated inflammatory complications
Taken together, these findings provide evidence that the novel Gp1ba-Cre mouse strain is highly efficient at ablating floxed genes in MKs, leading to an almost complete deletion of corresponding proteins in platelets. Reporter mouse experiments together with the lack of leukocyte-related phenotypes in Gp1ba-Cre-generated mice support MK lineagespecific transgene expression, which offers a powerful alternative strategy to generate MK/platelet-specific conditional KO mice.
Discussion
In this study, we report a new Cre deleter mouse strain that allows MK/platelet lineagespecific recombination of floxed genes. We demonstrate that 98.7% of platelets undergo recombination in Gp1ba-Cre +/KI mice. We show that this transgene is highly efficient at deleting proteins in platelets and results in similar platelet phenotypes to Pf4-Cre-generated Gp1ba was selected to drive Cre expression, because it is highly specific and drives high expression of GPIbα from an early stage during megakaryopoiesis. 44, 53 Although its specificity to the MK lineage is well established, a limited number of early studies reported GPIbα expression in cultured endothelial and smooth muscle cells. 54, 55 However, these findings were never validated by other groups or in vivo. 44 In our targeting strategy, we utilized the endogenous Gp1ba locus, thus Cre is controlled by the native promoter with its intact enhancer and repressor elements. In contrast, the Pf4-Cre mouse contains four additional chemokine genes as a consequence of the bacterial artificial chromosome construct utilized for its generation, namely Cxcl3, Cxcl5, Cxcl7 and Cxcl15. 8 Additional copies of these genes may explain the significantly lower platelet counts in the Pf4-Cre mouse, 9 but can also confound inflammatory and immune responses, as they are involved in modulating leukocyte recruitment and activation, [56] [57] [58] which is not an issue with our targeting strategy.
The T2A sequence used to couple Cre to GPIbα expression allows the equimolar expression of proteins from a single multi-cistronic transcript. 45 The T2A-based insertion results in addition of a short peptide sequence to the C-terminus of GPIbα, which may explain the observed reduction in GPIbα surface expression levels in Gp1ba-Cre mice.
Alternatively, reduced GPIbα expression might arise from less efficient chimeric mRNA transcription or reduced translation. The modest decrease in GPIbα likely underlies the marginal increase in platelet volume in Gp1ba-Cre KI/+ mice, which is well established in humans and mice with reduced GPIbα expression. 46, 47, 59 Although minor changes in platelet volume and receptor levels did not translate into defects in platelet function or hemostatic complications, we advocate using Gp1ba-Cre +/KI mice as controls for conditional KO mice generated with this strain, as is the case with Pf4-Cre-generated or any other conditional KO mouse models.
We demonstrate that 73.9% GPIbα hi MKs undergo recombination in the mT/mG;Gp1ba-Cre mice, pointing to high Cre expression in mature MKs. A possible reason for incomplete EGFP labeling of MKs is the short lag between GPIbα and Cre expression, recombination and EGFP accumulation. 38 GPIbα was recently reported in unipotent MK progenitors further supporting the lineage specificity of Gp1ba. 53 In contrast, CD41 is not exclusively MK-specific, but is also expressed on hematopoietic progenitors, [60] [61] [62] providing an explanation for the observed lower recombination of 55.3% of CD41 hi BM cells compared to GPIbα hi MKs. As a consequence, CD41-Cre mice are not suitable for generating MK/pltspecific KO mice. 60 A limitation of the Gp1ba-Cre mouse is that the onset of recombination occurs later than Pf4-Cre during megakaryopoiesis, resulting in later gene deletion, and a shorter timeframe for remaining mRNA and protein to be degraded. This is demonstrated by higher tdTomato signal in mT/mG +/fl ;Gp1ba-Cre +/KI MKs and platelets compared with mT/mG +/fl ;Pf4-Cre +/KI . Consequently, we found that 5-10% of targeted proteins persisted in Gp1ba-Cre-generated platelets, whereas only 1-6% protein levels remaining in Pf4-Cregenerated platelets. Several factors contribute to these differences in protein expression, including the onset of transgene and floxed gene expression, mRNA and protein stability. This is exemplified by Shp1 and Csk conditional KO models, which have more residual protein in platelets than CD148 conditional KO mice, due to earlier onset of gene expression.
An advantage of slightly higher residual protein levels is less severe developmental defects in MKs and platelets, providing more opportunity to investigate functional consequences of reduced protein expression. Dosing studies can also be designed by knocking out the same gene using the Pf4-Cre and Gp1ba-Cre transgenes, and comparing phenotypes of heterozygous and homozygous KO models in parallel. This can be particularly useful in studying megakaryopoiesis. In addition, Gp1ba-Cre-generated mouse models may more closely model hemizygosity in human patients. Incomplete protein ablation is not uncommon with other hematopoietic deleter strains. For example, the lifespan of circulating neutrophils in mice is less than a day, 63 and the protein ablation efficiency of the neutrophil lineagespecific Cre model Ly6G-Cre is approximately 55%. 64 With two complementary MK/platelet-specific deleter strains now at our disposal, we can address the issues of leakiness and dosing effects of gene expression in the MK lineage.
Importantly, we provide further evidence of the wide tissue expression of the Pf4-Cre transgene by analyzing mT/mG +/fl ;Pf4-Cre +/KI splenocytes. [9] [10] [11] Findings were corroborated with the Shp1 fl/fl ;Pf4-Cre +/KI mouse model. We observed recombination of ~15-50% of erythroid, myeloid and lymphoid cells, suggesting that Pf4 is expressed before MK lineage commitment. Of note, we detected 6.2% TER-119 + BM cell population in the mT/mG +/fl ;Gp1ba-Cre +/KI mice which underwent recombination, suggesting expression of GPIbα in a common MK-erythroid progenitor. Furthermore, we observed 4.7% EGFP + tdTomato + red pulp macrophages in these mice, which may represent recombined cells or macrophages that have phagocytosed EGFP + platelets. We are currently actively engaged in developing a more detailed expression pattern of Gp1ba-Cre, covering a range of cell and tissue types under normal and inflammatory conditions. This will be further advanced as the Gp1ba-Cre mouse becomes more widely used, as was the case of Pf4-Cre. [9] [10] [11] In summary, the Gp1ba-Cre mouse exhibits improved specificity towards the MK lineage compared with the existing Pf4-Cre mouse commonly used by platelet and leukocyte biologists. As proof-of-concept, we demonstrate that the motheaten-like hyper-inflammatory phenotype observed upon ablation of Shp1 with the Pf4-Cre transgene is absent in the Shp1 conditional KO mice generated with Gp1ba-Cre. These results discount the potential role of platelets in this phenotype and highlight the anomalies that arise from non-specific ablation in Pf4-Cre-generated KO mice. The more lineage-specific gene ablation provided by the Gp1ba-Cre mouse will make it possible to delineate the relative contribution of platelets to a variety of pathophysiological processes, and refine the involvement of leukocytes in thrombo-inflammatory conditions. The mouse Gp1ba gene consists of a 5' untranslated exon (1) followed by a short intron and an exon (2) containing the open reading frame encoding GPIbα protein. 59 Hemostatic response was measured in tail bleeding assays by an excision of a 5-mm portion of the tail tip followed by the determination of lost blood/body weight (normalized blood loss), n = 18 mice/genotype. Tail bleeding assays were conducted in a blinded manner.
Figure Legends
Unpaired, two-tailed t-test. 
